THERAPY DOSSIER · th-2e104b7db486

P7C3

Drug · No ChEMBL record under 'P7C3'; a preclinical aminopropyl carbazole NAMPT activator / NAD+ salvage enhancer. No ClinicalTrials.gov record (searched, not assumed).

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No ChEMBL record under 'P7C3'; a preclinical aminopropyl carbazole NAMPT activator / NAD+ salvage enhancer. No ClinicalTrials.gov record (searched, not assumed).
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31718264 ↗2019Reported benefit

Neuroprotective effects of P7C3 against spinal cord injury in rats.

RatSpinal cord injuryUnspecifiedSprague-DawleyFemaleSubcutaneous injectionAdministered after spinal cord injury; exact interval to first dose not stated

Model: Acute spinal cord injury in a rat model; specific injury mechanism, level and severity not stated in the retrieved abstract

P7C3 treatment improved functional recovery and tissue repair after spinal cord injury. Improved locomotor function correlated with increased survival of neurons and oligodendrocytes and with proliferation of oligodendrocytes and their progenitors, resulting in greater myelination and tissue repair…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…